caa a22 4500 475847032 CHVBK 20180406123917.0 cr unu---uuuuu 170329e20000701xx s 000 0 eng 10.1023/A:1008913209828 doi (NATIONALLICENCE)springer-10.1023/A:1008913209828 A new treatment satisfaction measure for asthmatics: A validation study [Elektronische Daten] [Susan Mathias, Elisabeth Warren, Hilary Colwell, Jennifer Sung] The Patient Satisfaction with Asthma Medication (PSAM) questionnaire was developed because no treatment satisfaction questionnaire could be identified that was comprehensive yet brief enough for use in clinical trials. Adult moderate asthmatics residing in Canada using an inhaled medication (either salmeterol, formoterol, or albuterol) self-administered the questionnaire, which also included the Asthma Quality of Life Questionnaire (AQLQ). A total of 53 asthmatics (70% female, 45% married, mean age: 47 years) completed the questionnaire. Using variable clustering, four PSAM scales were identified: Inhaler Properties, Comparison with Other Medications, Overall Perception of Medication, and Relief. Internal-consistency reliability provided evidence of reliability and lack of redundancy (Cronbach's Alpha: 0.82-0.88). Test-retest reliability was acceptable (ICC values at or near 0.70). As expected, interscale PSAM correlations were moderate to high; correlations between the PSAM and the AQLQ were low to moderate. To assess known groups validity, respondents were categorized by self-reported degree of asthma control: ‘very well controlled' ‘somewhat controlled', and ‘not well controlled'. Significant between-groups differences were found on all PSAM scales except Inhaler Properties. Patients categorized as ‘very well controlled' tended to report highest PSAM scale scores. The PSAM questionnaire demonstrated reliability and validity in moderate asthmatics. Responsiveness should be assessed in future, prospective studies. Kluwer Academic Publishers, 2000 Asthma nationallicence Quality of life nationallicence Questionnaire nationallicence Satisfaction nationallicence Validation nationallicence Mathias Susan The Lewin Group, 490 Second Street, Suite 201, 94107, San Francisco, CA, USA aut Warren Elisabeth The Lewin Group, 490 Second Street, Suite 201, 94107, San Francisco, CA, USA aut Colwell Hilary The Lewin Group, 490 Second Street, Suite 201, 94107, San Francisco, CA, USA aut Sung Jennifer Novartis Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ, USA aut Quality of Life Research Kluwer Academic Publishers 9/7(2000-07-01), 873-882 0962-9343 9:7<873 2000 9 11136 https://doi.org/10.1023/A:1008913209828 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1008913209828 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mathias Susan The Lewin Group, 490 Second Street, Suite 201, 94107, San Francisco, CA, USA aut NATIONALLICENCE 700 1- Warren Elisabeth The Lewin Group, 490 Second Street, Suite 201, 94107, San Francisco, CA, USA aut NATIONALLICENCE 700 1- Colwell Hilary The Lewin Group, 490 Second Street, Suite 201, 94107, San Francisco, CA, USA aut NATIONALLICENCE 700 1- Sung Jennifer Novartis Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ, USA aut NATIONALLICENCE 773 0- Quality of Life Research Kluwer Academic Publishers 9/7(2000-07-01), 873-882 0962-9343 9:7<873 2000 9 11136 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer